Biotech Values

[DewDiligence]

MRK reports that 44% and 46% of patients in the Boceprevir SPRINT-2 and RESPOND-2 studies, respectively, stopped treatment early according to the response-guided protocol in these studies:

http://finance.yahoo.com/news/Mercks-Investigational-bw-1755524465.html?x=0&.v=1

Early response-guided stopping occurred after 28 weeks in the SPRINT-2 study in the first-line setting (which included a 4-week lead-in period on SoC only) and after 36 weeks in the RESPOND-2 study in the second-line (for non-null-responders in the first line).